Phase 1Active, not recruiting
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
- Sponsor
- Stanford University (Academic or other)
- Enrolment
- 8 enrolled
- Conditions
- Lymphoblastic Leukemia
- Interventions
- Dasatinib
- Ages
- adults, older adults
- Registry
- NCT05993949
Full record on ClinicalTrials.gov
From the registry
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Primary outcomes
- Feasibility of dasatinib pulses
History
Study completion expected
Last registry update
Primary completion
Started
Registered